title: Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?
authors.affiliation: Hospital Universitario La Princesa, Madrid, Spain rcolomer@seom.org.
authors.forename: Ramon
authors.initials: R
authors.lastname: Colomer
authors.affiliation: Hospital Universitario La Princesa, Madrid, Spain.
authors.forename: Tomás
authors.initials: T
authors.lastname: Pascual
authors.affiliation: Hospital del Mar, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Albanell
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D003362:Cost-Benefit Analysis; D006801:Humans; D019057:Quality-Adjusted Life Years
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab